Skip to content

Construction and Application of Psoriasis Therapeutic effect Evaluation system based on Bayesian Network maximum Entropy self-Learning Model

Construction and Application of Psoriasis Therapeutic effect Evaluation system based on Bayesian Network maximum Entropy self-Learning Model

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035919
Enrollment
Unknown
Registered
2020-08-20
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Group A-Blood Heat Syndrome Group:Internal treatment: Chaiyin prescription (30g of stone cassia, 15g of Flos Lonicerae, 15g of Cortex moutan, 30g of Shengdi, 30g of Hedyotis diffusa, 30g of Daqing Lea
Group B-Blood stasis syndrome group:Internal treatment: Taodanfang (Astragalus 15g, licorice 10g, Angelica 15g, Chuanxiong 10g, peach kernel 10g, Salvia miltiorrhiza 30g, Zedoary 30g, Sichuan Achyrant
Group C-non-blood heat and blood stasis syndrome group:Internal treatment: the core prescriptions were treated based on syndrome differentiation, such as blood-cold syndrome, modified by Qinzhu Liangx

Sponsors

Yueyang Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Patients clearly diagnosed as psoriasis vulgaris; 2) Aged 18-60 years old; course of disease: 0-20 years; 3) Those who did not receive any drugs for the treatment of psoriasis within one month, and did not use hormone preparations within 6 months; 4) Informed consent, the patient signed the informed consent form, discussed through the ethics committee, and volunteered to receive treatment, observation and various examinations.

Exclusion criteria

Exclusion criteria: 1) Those who do not meet the diagnostic criteria; 2) Systematic treatment has been used within 3 months, including large areas of topical potent corticosteroids and immunosuppressants; 3) Patients with severe primary diseases and mental disorders such as heart, cerebrovascular, liver, kidney and hematopoietic system; 4) Pregnant, preparing for pregnancy or lactation; 5) Those who do not take the medicine in accordance with the regulations, can not judge the curative effect, or the data are incomplete, which affect the efficacy or safety judgment.

Design outcomes

Primary

MeasureTime frame
Psoriasis Area and Severity Index, PASI;Body Surface Area, BSA;Hamilton Depression Scale, HAMD;

Countries

China

Contacts

Public ContactLe-Kuai

Yueyang Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

mjbubu@qq.com+86 18018663707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026